Lactobacillus crispatus is a key strain of healthy vaginal flora. This probiotic bacterium supports the balance of your flora, the immune system, and protection against pathogens.
Lactobacillus crispatus is the dominant lactic acid bacterium of a healthy vaginal microbiome. It produces lactic acid and hydrogen peroxide, two compounds that maintain an acidic pH and protect the vaginal mucosa against pathogenic bacteria such as Gardnerella vaginalis or Escherichia coli.
What is Lactobacillus crispatus?
Lactobacillus crispatus is a lactic acid bacterium belonging to the family Lactobacillaceae, in the phylum Bacillota. This common rod-shaped species naturally colonizes the vaginal microbiota of a large proportion of healthy women.
Its central role comes from a major discovery of recent research: the concept of Community State Type I (CST I). This type of vaginal microbiota is dominated by L. crispatus and is associated with the best vaginal health outcomes according to 2025 data.
Unlike other lactobacilli such as L. iners or L. gasseri, L. crispatus offers more stable protection against dysbiosis. Its full correct name with author is Lactobacillus crispatus (Brygoo and Aladame 1953) Moore and Holdeman 1970.
A recent scientific discovery: beta-carbolines
A study published in October 2024 in Cell Host & Microbe by Smita Gopinath's team (Harvard T.H. Chan School of Public Health) identified a previously unknown family of molecules. Lactobacillus crispatus produces nine compounds called beta-carbolines, six of which show measurable anti-inflammatory effects.
This discovery better explains the role of this key strain in the immune response at the vaginal epithelium level. It also opens up new avenues for strategies to support the vaginal microbiota.
Our formula to support your intimate flora
To support the balance of your vaginal microbiota daily, we have developed Intimate Flora Probiotic. This formula combines the documented strains Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 in a gastro-resistant capsule, manufactured in France.
Discover Intimate Flora ProbioticWhat are the 5 benefits of Lactobacillus crispatus?
The benefits of Lactobacillus crispatus stem from its unique mechanisms of action on the vaginal microbiota. Here are the 5 main benefits documented by recent clinical research.
| Benefit | Mechanism of action | Level of evidence |
|---|---|---|
| Vaginal flora balance | Lactic acid production, acidic pH (< 4.5) | Randomized clinical trials |
| Protection against pathogens | Hydrogen peroxide, bacteriocins, protective biofilm | In vitro and in vivo studies |
| Immune system support | Anti-inflammatory beta-carbolines, exopolysaccharides | Harvard 2024, Nature 2026 |
| Reduction of urinary tract infection risk | Competition with E. coli in the vagina | Lactin-V Phase 2 trial |
| More stable pregnancy | Early dominance associated with fewer complications | Japanese cohort, 2025 |
Benefit 1: A healthy balance of vaginal flora
Lactobacillus crispatus converts sugars from vaginal cells into lactic acid. This biological process maintains an acidic pH around 4.0 to 4.5, a healthy vaginal environment hostile to pathogenic bacteria.
Benefit 2: Natural protection against pathogens
This key strain produces hydrogen peroxide, a natural antimicrobial. It also produces bacteriocins that target competing microbes such as Gardnerella vaginalis, Candida, or Escherichia coli.
Benefit 3: Immune system support
The exopolysaccharides (EPS) produced by L. crispatus modulate the local immune response. According to a study published in npj Biofilms and Microbiomes in 2026, they increase anti-inflammatory signals (TGF-beta-1, CST5) while reducing pro-inflammatory cytokines.
Benefit 4: Aid against recurrent urinary tract infections
A phase 2 clinical trial (Stapleton et al., Clinical Infectious Diseases) tested Lactin-V, a probiotic based on L. crispatus CTV-05. The rate of urinary tract infections was reduced by approximately 50% in women treated compared to placebo.
Benefit 5: A more serene pregnancy
A Japanese cohort published in Nature Communications in 2025 (Oguri et al.) followed the vaginal microbiota of pregnant women. Early dominance of Lactobacillus crispatus is associated with better gestational outcomes.
Read also: To learn more about intimate hygiene, discover our article dedicated to bacterial vaginosis.
How does Lactobacillus crispatus protect against pathogens?
Lactobacillus crispatus uses four distinct biological mechanisms to defend the vaginal ecosystem. These processes work synergistically and create a vaginal environment unfavorable to pathogenic bacteria.
The 4 defense mechanisms of L. crispatus
- Acidification of the environment: lactic acid production lowers vaginal pH below 4.5, a level that inhibits the growth of anaerobes responsible for bacterial vaginosis.
- Hydrogen peroxide production: this natural antimicrobial compound destroys the membranes of pathogenic bacteria and limits the development of Candida.
- Competition for adhesion: the strain occupies the vaginal epithelium and physically prevents pathogenic microbes from attaching to it.
- Protective biofilm: L. crispatus forms a beneficial biofilm on the vaginal mucosa, which acts as a natural barrier against aggressions.
These mechanisms explain why an absence of flora dominated by L. crispatus increases the risk of vaginal infection. Recent clinical data confirm the link between vaginal dysbiosis and vulnerability to pathogens.
Lactobacillus crispatus and intimate health: vaginal flora, urinary tract infections
Female intimate health largely depends on the balance of the vaginal microbiota. Lactobacillus crispatus plays a central role in preventing recurrent urinary and vaginal tract infections.
Bacterial vaginosis and microbiota
Bacterial vaginosis affects approximately 25% of women worldwide. It occurs when dominant lactobacilli are replaced by anaerobic bacteria. A randomized trial published in npj Biofilms Microbiomes in 2025 (Ravel et al.) showed that a multi-strain synbiotic based on L. crispatus allowed conversion to CST I type in 90% of participants, compared to 11% with placebo.
Recurrent urinary tract infections
Almost a quarter of women who have had a urinary tract infection develop a new one within 6 months. The presence of L. crispatus in the vagina reduces colonization by Escherichia coli, which is responsible for most cystitis.
Menopause and vaginal dryness
With the drop in estrogens during menopause, the vaginal microbiota changes and L. crispatus becomes scarcer. This change contributes to vaginal dryness and reduced protection. Targeted microbiota support can accompany this hormonal transition.
How to naturally support the presence of Lactobacillus crispatus?
Supporting the presence of Lactobacillus crispatus in your vaginal flora involves simple habits and an adapted lifestyle. Several factors directly influence bacterial balance.
The 6 habits that promote your flora
- Avoid vaginal douches and scented soaps that disrupt vaginal pH.
- Use a mild soap for external cleansing, never inside the vagina.
- Wear cotton underwear and avoid tight synthetic fabrics.
- Protect yourself during sexual intercourse to limit flora imbalances.
- Opt for a diet rich in fiber, prebiotics, and fermented foods.
- Manage chronic stress, which weakens the immune system and makes the microbiota fragile.
The role of targeted probiotics
A probiotic food supplement can support your intimate flora, especially after antibiotic therapy or during periods of imbalance. Documented strains such as Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 are studied orally for their effect on the vaginal microbiota. Lactobacillus crispatus, on the other hand, is still primarily studied vaginally in recent clinical trials.
Safety advice
Before starting any treatment, consult your doctor.
FAQ: your questions about Lactobacillus crispatus
Is Lactobacillus crispatus the same bacterium as Lactobacillus rhamnosus?
No. These are two distinct species of the Lactobacillus genus. L. crispatus dominates healthy vaginal flora, while L. rhamnosus is more studied for the intestinal microbiota and, for certain strains like GR-1, for supporting intimate flora orally.
Can Lactobacillus crispatus be taken orally?
Recent clinical trials mainly use the vaginal route for L. crispatus. Orally, other strains like L. rhamnosus GR-1 and L. reuteri RC-14 are better documented for reaching the vaginal flora via the gut-vagina axis.
How long does it take to see the effects of an intimate flora probiotic?
Clinical studies generally observe changes in the vaginal microbiota after 4 to 12 weeks of regular intake. The duration varies depending on the strain, dose, and the initial state of your flora.
Does Lactobacillus crispatus have side effects?
Clinical trials report very good tolerance. Some cases of mild irritation or transient vaginal discharge have been described. Consult a healthcare professional if in doubt, especially during pregnancy.
What is the difference between L. crispatus and L. iners?
Both species are common in the vagina, but L. crispatus is associated with a more stable and protective microbiota (CST I), whereas L. iners corresponds to a more fragile profile (CST III), more prone to imbalances.
Can a probiotic replace antibiotic treatment?
No. A probiotic is not a medicine and never replaces a prescribed treatment. It can be used to support the microbiota, with your doctor's agreement, during or after antibiotic therapy.
Is Lactobacillus crispatus useful for prevention, not just in case of infection?
Yes. Recent clinical data suggest that maintaining a microbiota dominated by L. crispatus (CST I) reduces the frequency of recurrent vaginal and urinary infections in predisposed women.
Scientific sources
- Ravel J, Simmons S, Jaswa EG et al. Impact of a multi-strain L. crispatus-based vaginal synbiotic on the vaginal microbiome: a randomized placebo-controlled trial. npj Biofilms and Microbiomes, 2025;11:158. Link
- Harvard T.H. Chan School of Public Health. Vaginal microbiome research uncovers new findings for women's health, October 2024 (Gopinath et al., Cell Host & Microbe study). Link
- Oguri N, Kobayashi C, Ozawa Y et al. Vaginal Lactobacillus crispatus in early pregnancy associates with favorable gestational outcomes in a Japanese maternal-neonatal microbiome cohort. Nature Communications, 2025;16:8032. Link
- Stapleton AE, Au-Yeung M, Hooton TM et al. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clinical Infectious Diseases, 2011 (historical reference still cited in 2025 by Frontiers, ASM and npj Biofilms). Link
